Literature DB >> 2444614

A STLV-III related human retrovirus, HTLV-IV: analysis of cross-reactivity with the human immunodeficiency virus (HIV).

F Barin1, F Denis, A Baillou, G Leonard, M Mounier, S M'Boup, G Gershy-Damet, A Sangare, P Kanki, M Essex.   

Abstract

A category of viruses has been identified which is related to human immunodeficiency virus (HIV) but is more closely related to a group of simian retroviruses (STLV-III). These viruses named HTLV-IV, LAV-II, or SBL-6669, are prevalent in West-Africa. In this study, we analysed the cross-reactivity at the protein level between HTLV-IV and HIV (HTLV-IIIB). The results indicate that most people infected with HTLV-IV have antibodies that react to the major gag protein of HIV p 24. There is also a high degree of immunologic cross-reactivity between the pol gene products of HIV and HTLV-IV. Among these the endonuclease/integrase is more conserved than the reverse transcriptase. In contrast, the envelope glycoproteins that are the most frequently detected antigens by antibodies from exposed individuals are serotype specific. These data make the env gene products the most interesting antigens for serotype specific diagnosis of human retroviruses infections.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2444614     DOI: 10.1016/0166-0934(87)90068-1

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  2 in total

1.  Specificity of new peptide immunoassays versus other immunoassays and agglutination tests for detection of HIV antibody in African sera.

Authors:  G Léonard; M Verdier; A Sangaré; J L Rey; F Denis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-08       Impact factor: 3.267

2.  Comparison of 10 enzyme immunoassays for detection of antibody to human immunodeficiency virus type 2 in West African sera.

Authors:  F Denis; G Leonard; A Sangare; G Gershy-Damet; J L Rey; B Soro; D Schmidt; M Mounier; M Verdier; A Baillou
Journal:  J Clin Microbiol       Date:  1988-05       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.